Report on the third FDA–AACR oncology dose-finding workshop

Leisha A. Emens, Rene Bruno, Eric H. Rubin, Elizabeth M. Jaffee, Amy E. McKee

Research output: Contribution to journalArticlepeer-review


The FDA–AACR Oncology Dose-Finding Workshop, Part 3, was held in Washington, DC, on July 20, 2017, as a continuation of the previous two collaborative dose-finding and optimization workshops presented by the FDA and AACR. This year's workshop focused on combination therapy with immune-oncology agents and best practices regarding patient and dose selection, predictive biomarkers, and novel clinical endpoints. This summary highlights viewpoints that emerged during the workshop.

Original languageEnglish (US)
Pages (from-to)1058-1061
Number of pages4
JournalCancer Immunology Research
Issue number12
StatePublished - Dec 2017

ASJC Scopus subject areas

  • Immunology
  • Cancer Research


Dive into the research topics of 'Report on the third FDA–AACR oncology dose-finding workshop'. Together they form a unique fingerprint.

Cite this